41 search results for: quality of life

The Relationship Between Skin Barrier Dysfunction and Increased Risk <b>of</b> Allergen Sensitization in AD

expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

3 min

Dermatology

Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.

Type 2 Inflammation Is a Significant Driver <b>of</b> Pediatric Severe Asthma

Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients

High Burden <b>of</b> Atopic Dermatitis in Children

expert video

High Burden of Atopic Dermatitis in Children

1 min

Dermatology

Explore the debilitating effects that impact day-to-day functioning in pediatric patients with atopic dermatitis – a short soundbite from EADV 2022.

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense <b>of</b> Smell?

expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

5 min

Rhinology

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

GINA-Based Opportunities for Improved Outcomes With Effective Management <b>of</b> Pediatric Asthma in Children 6-11 Years <b>of</b> Age

interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

10 min

Dermatology

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

8 min

Rhinology

Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.

expert video

Atopic Dermatitis Leads to Sleep Disruption for Children and Their Caregivers

1 min

Dermatology

Explore the impact of moderate-to-severe atopic dermatitis on sleep in pediatric patients – a short soundbite from EADV 2022.

expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

3 min

Dermatology

Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.

expert video

KOL Video Interview – Dr. Eric Simpson

5 min

Dermatology

In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.

expert video

How Should We Define and Classify Prurigo Nodularis?

13 min

Dermatology

Dr. Sarina Elmariah explains how to recognize and classify PN, using clinical examples and comparisons with related conditions. She then discusses PN assessment in clinical studies and practice, and the unmet needs in disease understanding and diagnosis.

expert video

ERS 2024 | What Do We Know About IL-33 Genetics?

14 min

Pulmonology

Dr. Stephanie Christenson examines the genetic and environmental factors influencing IL-33 expression and activity in COPD, highlighting the complex interplay between genetics, smoking, and disease pathogenesis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IsraelChange country/region